{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:13Z","timestamp":1793383033567,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"PinneyAssociates"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Preventive Medicine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ypmed.2019.105851","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T18:44:30Z","timestamp":1571683470000},"page":"105851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Risk of death associated with kratom use compared to opioids"],"prefix":"10.1016","volume":"128","author":[{"given":"Jack E.","family":"Henningfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2302-8949","authenticated-orcid":false,"given":"Oliver","family":"Grundmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane K.","family":"Babin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reginald V.","family":"Fant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Cone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ypmed.2019.105851_bb0005","author":"American Kratom Association"},{"issue":"4","key":"10.1016\/j.ypmed.2019.105851_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/a-0770-3683","article-title":"Comparative pharmacokinetics of mitragynine after oral administration of Mitragyna speciosa (Kratom) leaf extracts in rats","volume":"85","author":"Avery","year":"2019","journal-title":"Planta Med."},{"issue":"1","key":"10.1016\/j.ypmed.2019.105851_bb0015","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3390\/molecules15010432","article-title":"In vitro and in vivo effects of three different Mitragyna speciosa Korth leaf extracts on phase II drug metabolizing enzymes\u2014glutathione transferases (GSTs)","volume":"15","author":"Azizi","year":"2010","journal-title":"Molecules"},{"key":"10.1016\/j.ypmed.2019.105851_bb0020","author":"Babin"},{"key":"10.1016\/j.ypmed.2019.105851_bb0025","unstructured":"Centers for Disease Control and Prevention (CDC) (2018) Drug overdose deaths at https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html (Accessed on August 4, 2019)."},{"key":"10.1016\/j.ypmed.2019.105851_bb2225","series-title":"Substance Abuse and Mental Health Services Administration","article-title":"2017 National Survey on Drug Use and Health: Detailed Tables","author":"Center for Behavioral Health Statistics and Quality","year":"2018"},{"key":"10.1016\/j.ypmed.2019.105851_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","article-title":"Kratom as a substitute for opioids: results from an online survey","volume":"202","author":"Coe","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2019.105851_bb0035","unstructured":"Food and Drug Administration (2017) Basis for the Recommendations to Control Mitragynine and 7-Hydroxymitragynine in Schedule I of the Controlled Substances Act. https:\/\/www.documentcloud.org\/documents\/5031552-HHS-kratom-letter.html (Accessed on May 1, 2019)."},{"key":"10.1016\/j.ypmed.2019.105851_bb0040","unstructured":"Galvin, G. (2019). CDC Study Shows Kratom-Linked Overdose Deaths. U.S. News & World Reports. https:\/\/www.usnews.com\/news\/health-news\/articles\/2019-04-11\/kratom-linked-overdose-deaths-examined-in-cdc-study. (Accessed on April 30th, 2019)."},{"issue":"1","key":"10.1016\/j.ypmed.2019.105851_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1056\/NEJMc1811055","article-title":"Deaths in Colorado attributed to Kratom","volume":"380","author":"Gershman","year":"2019","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.ypmed.2019.105851_bb0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","article-title":"Patterns of Kratom use and health impact in the US-results from an online survey","volume":"176","author":"Grundmann","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2019.105851_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","article-title":"Patterns of Kratom use and health impact in the US\u2014results from an online survey","volume":"176","author":"Grundmann","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"10","key":"10.1016\/j.ypmed.2019.105851_bb0060","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/add.14371","article-title":"The therapeutic potential of kratom","volume":"113","author":"Grundmann","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.ypmed.2019.105851_bb0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","article-title":"The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research","volume":"235","author":"Henningfield","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ypmed.2019.105851_bb0070","author":"Henningfield"},{"issue":"6408","key":"10.1016\/j.ypmed.2019.105851_bb0075","doi-asserted-by":"crossref","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.ypmed.2019.105851_bb0080","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/bmc.731","article-title":"A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats","volume":"21","author":"Janchawee","year":"2007","journal-title":"Biomed. Chromatogr."},{"issue":"11","key":"10.1016\/j.ypmed.2019.105851_bb0085","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/00498254.2018.1552819","article-title":"Metabolite profiling and identification of enzymes responsible for the metabolism of mitragynine, the major alkaloid of Mitragyna speciosa (kratom)","volume":"49","author":"Kamble","year":"2019","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ypmed.2019.105851_bb0090","series-title":"More Deaths Have Been Associated With Kratom Than Previously Known","author":"Kaur","year":"2019"},{"key":"10.1016\/j.ypmed.2019.105851_bb2230","series-title":"National Vital Statistics Reports","article-title":"Deaths: Final data for 2017","volume":"68","author":"Kochanek","year":"2019"},{"key":"10.1016\/j.ypmed.2019.105851_bb0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neuropharm.2017.08.026","article-title":"The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse","volume":"134","author":"Kruegel","year":"2018","journal-title":"Neuropharmacology"},{"issue":"21","key":"10.1016\/j.ypmed.2019.105851_bb0100","doi-asserted-by":"crossref","first-page":"6754","DOI":"10.1021\/jacs.6b00360","article-title":"Synthetic and receptor signaling explorations of the Mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators","volume":"138","author":"Kruegel","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.ypmed.2019.105851_bb0105","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1021\/acscentsci.9b00141","article-title":"7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects","volume":"5","author":"Kruegel","year":"2019","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.ypmed.2019.105851_bb0110","first-page":"145","article-title":"Some observations on the pharmacology of mitragynine","volume":"198","author":"Macko","year":"1972","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.ypmed.2019.105851_bb0115","unstructured":"Miller, R. (2019) Herbal drug kratom linked to almost 100 overdose deaths, CDC says. https:\/\/www.usatoday.com\/story\/news\/health\/2019\/04\/11\/kratom-herbal-drug-linked-overdose-deaths-cdc-says\/3441560002\/. (Accessed on April 30th, 2019)."},{"key":"10.1016\/j.ypmed.2019.105851_bb0120","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/j.ypmed.2019.105851_bb0125","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/j.ypmed.2019.105851_bb0130","author":"National Institute on Drug Abuse (NIDA)"},{"key":"10.1016\/j.ypmed.2019.105851_bb0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.15585\/mmwr.mm6814a2","article-title":"Notes from the Field: unintentional drug overdose deaths with Kratom detected \u2014 27 states, July 2016\u2013December 2017","volume":"68","author":"Olsen","year":"2019","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.ypmed.2019.105851_bb0145","doi-asserted-by":"crossref","unstructured":"Papsun, D.M., Chan-Hosokawa, A., Friederich, L., Brower, J., Graf, K., and Logan, B. (2019). The trouble with kratom: analytical and interpretative issues involving mitragynine, J. Anal. Toxicol., Published online August 19, 2019 at doi:https:\/\/doi.org\/10.1093\/jat\/bkz064.","DOI":"10.1093\/jat\/bkz064"},{"key":"10.1016\/j.ypmed.2019.105851_bb0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drugpo.2019.05.003","article-title":"Kratom policy: the challenge of balancing therapeutic potential with public safety","volume":"70","author":"Prozialeck","year":"2019","journal-title":"Int. J. Drug Pol."},{"issue":"3","key":"10.1016\/j.ypmed.2019.105851_bb0155","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jep.2013.02.008","article-title":"Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats","volume":"146","author":"Sabetghadam","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ypmed.2019.105851_bb0165","doi-asserted-by":"crossref","unstructured":"Scholten, W. and Henningfield, J.E. (2016a) Negative outcomes of unbalanced opioid policy supported by clinicians, politicians, and the media. J. Pain Palliative Care Pharmacother. 2016;30(1):4\u201312.","DOI":"10.3109\/15360288.2015.1136368"},{"issue":"4","key":"10.1016\/j.ypmed.2019.105851_bb0170","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1080\/15360288.2016.1241335","article-title":"Negative outcomes of unbalanced opioid policy supported by clinicians, politicians, and the media. Letter of response to Kolodny","volume":"30","author":"Scholten","year":"2016","journal-title":"J. Pain Palliative Care Pharmacother."},{"issue":"3","key":"10.1016\/j.ypmed.2019.105851_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2582","article-title":"Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia","volume":"32","author":"Singh","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.ypmed.2019.105851_bb0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jep.2017.12.017","article-title":"Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia","volume":"214","author":"Singh","year":"2018","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.ypmed.2019.105851_bb0185","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.drugalcdep.2017.08.034","article-title":"Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program","volume":"180","author":"Smith","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ypmed.2019.105851_bb0190","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.ypmed.2019.105851_bb0195","author":"Sullum"},{"key":"10.1016\/j.ypmed.2019.105851_bb0200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.drugalcdep.2017.10.012","article-title":"Kratom use and mental health: a systematic review","volume":"183","author":"Swogger","year":"2018","journal-title":"Drug Alcohol Depend."},{"issue":"18","key":"10.1016\/j.ypmed.2019.105851_bb0205","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit \u03b2-arrestin-2","volume":"59","author":"V\u00e1radi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ypmed.2019.105851_bb0210","doi-asserted-by":"crossref","DOI":"10.2147\/SAR.S164261","article-title":"Current perspectives on the impact of Kratom use","author":"Veltri","year":"2019","journal-title":"Subs. Abuse Rehabil."}],"container-title":["Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519303275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091743519303275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:01:11Z","timestamp":1758794471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091743519303275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":42,"alternative-id":["S0091743519303275"],"URL":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.105851","relation":{},"ISSN":["0091-7435"],"issn-type":[{"value":"0091-7435","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of death associated with kratom use compared to opioids","name":"articletitle","label":"Article Title"},{"value":"Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ypmed.2019.105851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105851"}}